Latest news with #MattSteinberg
Yahoo
4 days ago
- Business
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.
Yahoo
11-05-2025
- Business
- Yahoo
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Elutia Inc (NASDAQ:ELUT) reported a 31% year-over-year growth in its bio envelope division, reaching $3.1 million in revenue. The company successfully launched its LEU Pro product, which now constitutes 52% of the bio envelope revenue, showing an 84% increase from the previous quarter. Elutia Inc (NASDAQ:ELUT) formed a strategic partnership with Boston Scientific, expanding its commercial footprint to over 900 sales professionals. The company opened a new facility in Gaithersburg, Maryland, to enhance manufacturing capacity and reduce production costs. Elutia Inc (NASDAQ:ELUT) received an Edison Award for innovation in post-surgical recovery, highlighting its commitment to advancing medical technology. Revenue from the Simple Derm division decreased from $3.6 million last year to $2.6 million this quarter. The cardiovascular products division reported only $300,000 in sales, as it was still transitioning from an outside distributor. Overall sales were down from the previous year, despite a sequential increase from the fourth quarter. The company faced production constraints due to the antibiotic component of LEU Pro, necessitating the opening of a new facility. Elutia Inc (NASDAQ:ELUT) had to manage cash flow carefully, including a registered direct offering and amendments to financial agreements to conserve cash. Warning! GuruFocus has detected 6 Warning Signs with ELUT. Q: How have the relationships with physicians gone in the cases where Boston Scientific reps are involved? Are they fully switching to LU Pro, or is it a gradual process? A: Randy Mills, CEO: The adoption pattern for LU Pro typically starts with one physician in a practice showing interest and using the product. Once they experience the benefits, particularly if they've used competitive products before, it tends to spread through the practice. The conversion is not limited to Boston Scientific cases; it often extends to other cases as well, making it a valuable partnership for both Elutia and Boston Scientific. Q: What is the current manufacturing capacity for LU Pro, and how much revenue can it support before reaching constraints? A: Randy Mills, CEO: Our current manufacturing capacity can support about $140 million in LU Pro revenue annually. However, the production of the antibiotic disk component is a constraint, limiting capacity to $25-30 million annually. We are expanding to address this bottleneck. Q: How should we think about the cash burn profile going forward, considering the growth of LU Pro and the cardiovascular products coming in-house? A: Matt Steinberg, CFO: The cash flow from operations in Q1 was about $8.1 million, including $4 million related to litigation settlement. We expect cash burn to decrease as we move through the year, likely returning to a more historic range of $4-5 million. Q: How will the registry study data support commercial conversions and broader clinical adoption over the next 12-18 months? A: Randy Mills, CEO: The registry study data will be more impactful in the second half of next year when publications are available. This data, along with existing clinical and scientific studies, will bolster our value analysis committee submissions and support regulatory submissions outside the U.S. Q: What is the expected pace of mix shift towards LU Pro in the bio envelope category, and how will it affect Kangaroo sales? A: Randy Mills, CEO: LU Pro is expected to significantly outpace Kangaroo, with potential U.S. revenue of about $200 million at maturity compared to Kangaroo's $10 million. While Kangaroo will remain for certain patient populations, LU Pro is rapidly gaining market share, now constituting over 50% of bio envelope revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Chicago Tribune
21-03-2025
- Sport
- Chicago Tribune
Loud? Proud? Matt Steinberg is ready to show off quieter pitching side for St. Laurence East. ‘I'm really excited.'
It's something St. Charles East pitcher Matt Steinberg wishes he had done a long time ago. In the offseason, the senior right-hander put in extensive work to quiet down his maximum-effort delivery on the mound and become more efficient. The results of that work have Steinberg poised for a big season. 'I was really working with the guys at Athletes HQ (in Elgin) to really hone in on my mechanics, work on some detailed stuff to hopefully bring to the mound,' Steinberg said. 'So far, it's worked out. My velocity has jumped. My control has jumped. My off-speed has been amazing. 'I'm really excited.' The Saints are excited too. After Steinberg established himself on the varsity level in the spring, the Manhattan recruit helped pitch the Saints to a summer state championship. Now, St. Charles East pitching coach Mark Foulkes sees a different person on the mound. 'Everything about him last year at times was so violent, his windup,' Foulkes said. 'Last summer he just slowed it down and really started to trust himself a lot more. 'This whole preseason, he's looked really, really good.' Steinberg's high school career was derailed as a sophomore when he tore his ACL. Following that rehab, he was back on the mound last spring, getting his first taste of varsity action. Fully healthy and returning with experience in big games, Steinberg wants to take the next step. 'He's a guy who you hope his hard work pays off,' St. Charles East coach Derek Sutor said of Steinberg. 'As a sophomore he tore his ACL, so he's had to come back from that. 'He's always had his head up. He's always been positive. He's put in hard work. You just hope for a kid like him that it finally pays off.' College coaches started to take notice over the summer. While the Saints were winning state at North Central College, Tim Stoddard began looking into Steinberg and teammate Nathan Beers. Stoddard, a former MLB pitcher, is NCC's pitching coach. Beers ended up committing to NCC. Derek Shomon, co-owner of Athletes HQ, was also impressed by workouts. He contacted friend Steven Rosen, who's Manhattan coach. Rosen hooked up with Steinberg, and the rest is history. Manhattan is a Division I program located in the Riverdale neighborhood of the Bronx in New York. 'They liked my film, liked my build,' Steinberg said. 'I went out in late October, gorgeous campus. It was a great experience. I'm blessed to have the opportunity to go out there and play. 'Last season, it's kind of all you can think about as someone who wants to play at the next level.' The 6-foot-3 Steinberg sits in the upper 80s with his fastball. He also has a breaking ball that he said he grips like a curveball but plays more like a slider thanks to his delivery. The pitch that sets him apart, however, is his change-up. Often the pitch that takes the longest to master, Steinberg said he started work on it as a kid. 'I always want to give myself an advantage in any way I can,' Steinberg said. 'It's a pitch that, for the most part, we know doesn't hurt your arm, so I developed it around the age of 10. 'It's always stuck with me.' He'll unleash that arsenal as part of a potent, veteran top three of the rotation for the Saints. Xavier-bound Joey Arend, the staff ace, is one of the most experienced players in the area. Steinberg and Beers slot in behind Arend in what Sutor calls the strength of the team. 'Winning the (summer) state tournament put a target on our back,' Steinberg said. 'We really hope to live up to those expectations and prove to everybody that we deserved the recognition. 'We hope to make a state run and get a state trophy in the trophy case at the end of the year.'
